1. Introduction {#Section1}
===============

Prostate cancer is the second most common malignancy in men globally, accounting for 1.1 million new cases and more than 300,000 cancer-related deaths worldwide in 2012 [@B1]. In the United States, there will be an estimated 164,690 new cases of prostate cancer to be diagnosed and 29,430 cancer-related deaths in 2018 [@B2]. The risk factors in the development of prostate cancer include an older age, a family history of prostate cancer, and race [@B3], [@B4]. The median age of prostate cancer diagnosis is 66 years, and the majority of prostate cancer survivors (64%) are over 70 years of age and it is rare to receive a prostate cancer diagnosis under the age of 50 years (less than 1%) [@B5]. Prostate cancer frequently metastasizes to the lymph node and bone [@B6], [@B7]. However, up to 15% of prostate cancer cases show metastasis to sites other than bone and regional lymph nodes at diagnosis [@B8], [@B9]. Treatment is not required for cases of low-grade prostate cancer occurring in elderly men, whereas cases with a higher Gleason score and metastasis can be treated through chemoradiotherapy, endocrine therapy or surgery [@B10]. Recently, local treatment has been tried for metastatic prostate cancer (mPCa), especially for oligo-metastatic cases [@B11].

Most localized prostate cancer cases have had favorable 5-year overall survival rate (99%), whereas only 28% of distantly mPCa show 5-year survival in the United States [@B10]. The prognosis of mPCa depends on different parameters of the clinicopathological factors, such as the level of the prostate-specific antigen (PSA) [@B12], the Gleason score [@B13], the lymph node status [@B14], and recurrence [@B15], [@B16]. A previous study showed that the age at diagnosis also plays an important role in the prognosis of prostate cancer [@B17]; there are few studies to date that have focused on the role of age in the survival of patients with mPCa. Recent studies have, however, evaluated the prognosis of castration-resistant prostate cancer with different metastatic sites [@B18], [@B19]. Thus, accurately understanding the characteristics of prostate cancer metastasis could help medical oncologists to predict the prognosis of prostate cancer and provide treatment decisions for these patients. In this study, we compared the clinicopathological features and survival of mPCa to stratify age and non-bone-related metastasis as prognostic factors.

2. Methods {#Section2}
==========

2.1 Database and patient selections {#Section2.1}
-----------------------------------

The Surveillance Epidemiology and End Results (SEER) database is a population-based cancer registration system that covers approximately 28% of the total population in the United States \[<https://seer.cancer.gov/>\]. In this study, we utilized the SEER\* Stat 8.3.5 software to query data from 18 SEER registries using the following criteria: primary prostate adenocarcinoma at all stages, including M1a-c \[AJCC cancer staging manual, 7th edition [@B20]. Patients with unknown sites of cancer metastasis, unknown ages, and unknown survival data were excluded.

2.2 Defining of metastasis sites {#Section2.2}
--------------------------------

The CS data collection system is a joint initiative, sponsored by the AJCC, to simplify staging data in cancer registrations. Specifically, the "CS mets at dx (2004+)" CS parameter includes information of the metastasis sites at diagnosis. We used this parameter in the search terms to obtain patients with information regarding metastatic sites, i.e., non-regional lymph nodes (NRLN) only metastasis (code, 11, 12, and 20), which has no visceral metastasis; bone only metastasis (code, 30), which has no visceral metastasis; bone + NRLN metastasis (code, 35), which has no visceral metastatic; all other sites ± NRLN metastasis (Code, 38, 40, 50, 58, and 55). Cases of visceral metastasis were divided into the lung only, liver only, and brain only metastases as well as the bone + lung, bone + liver, and bone + brain metastasis, namely the bone-related metastases.

2.3 Statistical analysis {#Section2.3}
------------------------

We utilized the X-tile software v3.6.1 (Yale University, New Haven, CT, USA) to determine the optimal cut-off values for age [@B21] and used SPSS v24.0 (SPSS Inc., Chicago, IL, USA) for all of the statistical analyses of the data. In brief, the clinicopathological characteristics of the patients were compared using Pearson\'s chi-square test and the Kaplan-Meier method was used to generate the overall survival for the log-rank test to assess differences in survival between groups. The multivariate Cox regression analysis was used to determine the association with overall survival (OS) rate and the OS rate was defined as the time from diagnosis of prostate cancer to death due to any cause. The hazards ratio (HR) and the 95% confidence interval (95% CI) were also generated for statistically significant values of data. A *p* value \< 0.05 was considered to be statistically significant.

3. Results {#Section3}
==========

3.1 Characteristics of patients {#Section3.1}
-------------------------------

In this study, we searched the SEER database to identify a total of 10,471 patients with mPCa who were diagnosed between 2010 and 2015. And we used the X-tile software to divide age into three groups (Figure [1](#F1){ref-type="fig"}). For example, among the total population of patients, 5378 (53%) were diagnosed at ages ≤ 70 years old, which we classified as the younger-aged group, 3140 (30.9%, 70-82 years old) patients were classified as the middle-aged group, and 1629 (16.1%) was placed in the elderly-aged group (\> 82 years old). The median age at prostate cancer diagnosis was 70 years old with an overall median follow-up time of 16 months and an interquartile range (IQR) of 7-30 months.

Significant differences were observed in the insurance and marital status, race, the PSA level, Gleason score, T staging, N staging, surgery, radiotherapy, chemotherapy, and metastasis sites between patients (P \< 0.001; Table [1](#T1){ref-type="table"}). Specifically, more Caucasian patients were diagnosed with mPCa in the elderly-aged group than in the younger- or middle-aged groups (69.1% vs. 77.7% and 82.4%, respectively, P \< 0.001). In addition, prostate cancer was more aggressive (T1/T2 vs. T3/T4 diseases) in patients in the younger-aged group than in the cases that were diagnosed in the middle- or elderly-aged groups (25.1% vs. 19.9% and 17%, respectively, P \< 0.001). The rate of the lymph node involvement was higher in the younger-aged group than in the middle- or elderly-aged groups (33.7% vs. 23.5% and 17.1%, P \< 0.001). However, data on the T stage and N stage were not available for all patients in this SEER database. In regards to treatment, the surgery and chemoradiotherapy rate was significantly higher in the patients in the younger- and middle-aged groups than in the patients in the elderly-aged group (P \< 0.001).

3.2 Age-related patterns of prostate cancer metastasis {#Section3.2}
------------------------------------------------------

Regarding the observation of single metastatic sites in these prostate cancer patients, bone metastasis was the most common metastatic site (70.6%), followed by NRLN (6.4%), the lung (1.4%), liver (0.7%), and brain (0.2%). In cases with multiple metastatic sites, bone-related metastases occurred commonly at the bone + NRLN (12.9%; n = 1313). The 8040 cases of single site metastasis were compared to the 2107 bone-related metastatic sites. We found that, compared to the results found in patients with a single metastatic site, bone and lung metastases were more often observed in patients in the older-aged group than in patients in the younger- or middle-aged groups (77.2% vs. 66.3% or 74.5%, respectively, or 1.9% vs. 1.2% and 1.4%, respectively; P \< 0.001). However, the proportion of NRLN metastasis was lower in patients of the older-aged group than in patients of the younger- or middle-aged groups (3.8% vs. 7.5% and 6.0%, respectively, P \< 0.001).

3.3 Univariate survival analysis of patients with mPCa {#Section3.3}
------------------------------------------------------

We then performed a univariate analysis of the patients with a single metastasis site for survival significance (Table [2](#T2){ref-type="table"}). Our data shows that age, insurance and marital status, race, the PSA level, Gleason score, tumor T, N, and M stages, surgery, and radiotherapy were prognostic factors for the overall survival (OS) rate (P \< 0.05). Moreover, compared with the cases of bone metastases, patients with NRLN or lung metastasis had a better OS rate (P \< 0.05), whereas patients with liver metastasis had a poor OS rate (P \< 0.05). However, there was no statistical significance in the OS rate of patients with brain metastasis (P = 0.19).

Furthermore, analysis of the data regarding patients with bone-related metastases showed that age, race, PSA level, Gleason score, tumor T and M stages, radiotherapy, and chemotherapy all had an effect on the OS rate (P \< 0.05; Table [3](#T3){ref-type="table"}). Compared with the data regarding patients with bone + NRLN metastasis, the OS rate of patients with bone + lung, bone + liver and bone + brain metastasis were poor (P \< 0.05). Figure [2](#F2){ref-type="fig"} shows the OS rate of the patients with a single metastasis and patients with bone-related metastasis.

3.4 Multivariate survival analysis of patients with single site metastases stratified by age {#Section3.4}
--------------------------------------------------------------------------------------------

We then performed multivariate analysis and found that metastasis sites, together with age, insurance and marital status, race, PSA level, Gleason score, tumor T and N stages, and surgery, were all independent prognostic predictors for the OS rate (P \< 0.05; Table [2](#T2){ref-type="table"}). We then stratified our data by age groups and found that there was a significant difference in the OS rate of patients with different metastatic sites (P \< 0.001, Fig. [3](#F3){ref-type="fig"}). In the younger age group, patients with NRLN metastasis had a better OS rate than those with bone metastasis (HR, 0.59, 95%CI, 0.47-0.73, P \< 0.001; Table [4](#T4){ref-type="table"}). In this age group, cases of liver metastasis tended to have the worst OS rate, although patients with PCa lung, brain, and bone metastases had a similar prognosis (P \> 0.05; Table [4](#T4){ref-type="table"}). In the middle-aged group, the risk of death for patients with NRLN and lung metastasis was similar. However, the prognosis of patients with NRLN and lung metastasis was better than that of cases of bone metastasis (P \< 0.05; Table [4](#T4){ref-type="table"}). Furthermore, the prognosis of patients with the liver and brain metastases was similar to those with bone metastases. In the older-aged group, there was no significant difference in the prognosis of patients with NRLN, lung, or brain metastasis (P \> 0.05; Table [4](#T4){ref-type="table"}). However, in this age group, the OS rate of patients with liver metastasis was still the worst (P = 0.009; Table [4](#T4){ref-type="table"}).

3.5 Multivariate survival analysis of patients with bone-related metastases stratified by age {#Section3.5}
---------------------------------------------------------------------------------------------

Our data shows that the metastatic site, together with age, race, Gleason score, tumor T stage, radiotherapy, and chemotherapy, were all independent prognostic predictors for the OS rate of patients with mPCa (P \< 0.001; Table [3](#T3){ref-type="table"}). Among the patients with bone-related metastases, there was poor an OS rate in patients with a Gleason score of 10 or more (HR, 1.67, 95%CI, 1.25-2.23, P \< 0.001) of T4 stage (HR, 1.39, 95%CI, 1.13-2.71, P = 0.002). Moreover, the Kaplan-Meier curves that were stratified by age show that there was a significant difference in the OS rate among patients with different organ metastases (P \< 0.001; Fig. [4](#F4){ref-type="fig"}). We analyzed the difference in the OS rate of patients with bone-related metastases among these three groups, stratified by patients\' age, and found that the metastatic sites in the middle- and elderly-aged groups had the same prognosis in terms of the bone-related metastases; thus, the data from these two groups were combined. In the younger aged group, there was no statistical difference in the OS rate in patients with bone + NRLN and patients with bone + lung metastasis (P \> 0.53; Table [5](#T5){ref-type="table"}). Compared to the results of patients with bone + NRLN metastasis, the OS rate of patients with bone + brain and bone + liver metastasis was poor (HR, 1.95, 95%CI, 1.20-3.16, P = 0.007 or HR, 2.20, 95%CI, 1.72-2.81, P \< 0.001; Table [5](#T5){ref-type="table"}). However, patients with bone + liver metastasis showed the worst OS rate.

In the elderly-aged group, the OS rate of patients with bone + liver or bone + lung metastasis was worse than those of patients with of bone + NRLN metastasis (HR, 2.22, 95%CI, 1.68-2.92, P \< 0.001 or HR, 1.54, 95% CI: 1.254 1.900, P \< 0.001; Table [5](#T5){ref-type="table"}). Patients with bone + liver metastasis had a higher risk of death than patients with bone + lung metastasis. There was no statistical significance in the difference in the OS rate of patients with bone + brain and bone + NRLN metastasis (P \> 0.05; Table [5](#T5){ref-type="table"}). Thus, our current study suggests that the OS rate of patients with bone + lung or bone + NRLN metastasis was similar in the younger patient population. However, the difference in the OS rate of patients with bone + brain or bone + NRLN metastasis in elderly-aged patients was not statistically significant.

4. Discussion {#Section4}
=============

During the past three decades, the incidence of cancer has increased globally and cancer prognosis is inversely associated with cancer invasion and metastasis [@B22]. Metastasis is a truly multifaceted process that involves tumor cell proliferation, migration, and invasion to nearby or distant lymph nodes or to the blood stream followed by the establishment of a metastatic site, angiogenesis, and formation of metastatic tumor lesions [@B23]. Prostate cancer usually metastasizes through lymph nodes to the bone or other organs. Approximately 15% of patients with prostate cancer have visceral metastases [@B6]. To date, there is no standard treatment for patients with mPCa; thus, the identification of patients with prostate cancer that have a better prognosis could provide us with guidelines for the selection of different treatment options.

In the current study, we compared the clinicopathological features and overall survival rate of patients with mPCa after stratification by the age of patients and by the observation of a single metastasis vs. bone-related metastases. We found that bone metastasis was the most common type of metastasis (70.6%), followed by NRLN (6.4%), the lung (1.4%), liver (0.7%), and brain (0.2%). In cases of mPCa with multiple metastatic sites, bone-related metastases occurred commonly at the bone + NRLN (12.9%; n = 1313). The multivariate survival analysis of patients with single site metastases showed that metastasis sites, age, insurance and marital status, race, PSA level, Gleason score, tumor T and N stages, and surgery were all independent prognostic predictors for the OS rate. Multivariate survival analysis of patients with bone-related metastases also showed that the metastatic sites, age, race, Gleason score, tumor T stage, radiotherapy, and chemotherapy were all independent prognostic predictors for the OS rate. In patients of the younger-aged group with a single metastatic site, patients with NRLN metastasis had a better OS rate than those with bone metastasis, while patients with liver metastasis had the worst OS rate. Moreover, in patients of the younger-aged group with multiple metastatic sites, there was no statistical difference in the OS rate of patients with bone + NRLN metastasis from patients with bone + lung metastasis. Compared to the results of patients with bone + NRLN metastasis, the OS rates of patients with bone + brain and bone + liver metastasis were poor. However, patients with bone + liver metastasis had the worst OS rate. In addition, in patients in the elderly-aged group with multiple metastasis sites, the OS rate of patients with bone + liver or bone + lung metastasis was worse than those of patients with of bone + NRLN metastasis, while patients with bone + liver metastasis has a higher risk of death than patients with bone + lung metastasis.

The reason for the observed high incidence of prostate cancer metastasis to the bone could be because of the interaction between metastatic prostate cancer cells and the bone microenvironment or because of the ability of the bone to attract tumor cells through the production and release of chemokines [@B24], [@B25]. Moreover, many age-related factors, including immune response and chronic inflammation, could also play a role in prostate cancer metastasis [@B26], [@B27]. The "seed and soil hypothesis" may partly explain the phenomenon of different metastasis sites and patterns for cancer metastasis [@B28]. Our current research revealed that older Caucasians and younger African Americans were more likely to develop mPCa, while younger patients with mPCa had higher T and N stages, which was consistent with previous findings [@B17]. In the current study, we selected the age of 70 years as the cut-off value. This age was selected for the following reasons: 1). The median age of the cohort of samples was 70 years old, 2). The X-tile software was used to select these three groups of age stratification and an age of less than 70 years old showed the best prognosis, and 3). Culp et al. showed that an age ≥ 70 years was a risk factor for patients undergoing local therapy to be associated with an increased risk of cancer-specific death [@B29].

Our current study demonstrated that, in elderly patients, the prognosis of prostate cancer patients with bone, NRLN, or lung metastasis is similar. This may be because this group of patients had other diseases or related complications; however, this study does not provide proof in support of this hypothesis and, thus, further prospective studies are required. Furthermore, patients with bone-related metastases, such as bone + lung or bone + NRLN metastasis also showed similar rates of OS in the younger group, whereas patients with bone + liver or bone + brain metastasis in the elderly age group had a poor OS rate. According to previous studies, prostate cancer patients with bone ± NRLN metastasis were generally treated locally, through cytoreductive prostatectomy or radiotherapy to improve prognosis [@B30], [@B31]. However, most of these studies excluded prostate cancer patients with visceral metastasis, leading to a poor prognosis of patients with visceral metastasis [@B32]. Our current data indicate that prostate cancer with bone + lung or bone + NRLN metastasis had similar prognosis in younger patients; thus, we may consider more radical treatment options to improve their prognosis. In addition, the elderly-aged group of patients with prostate cancer that had bone + lung metastasis had a higher death risk than those with bone + NRLN metastasis. We therefore, speculate that treatment of prostate cancer patients with metastasis could be more personalized to improve the survival rate of patients as well as the quality of life. Thus, our current study suggests that 1) differences in the baseline characteristics of mPCa cases, such as age, could alter the treatment options and survival rates of patients; 2) our current data could help us to better understand the biological characteristics of the disease, leading to the development of novel treatment strategies [@B33]. For example, individuals with visceral metastasis often had a poor prognosis; thus, metastasis-directed treatment options led to improving the prognosis of mPCa [@B34].

To date, the treatment of prostate cancer that is selected depends on the stage of the disease, the Gleason score, and the PSA level for surgery and chemical/radiotherapy; however, age and patient health, and persons\' views of treatment effectiveness, and their possible side effects should also be taken into account, in addition to quality of life and life expectations [@B35]-[@B39]. Furthermore, based on age grouping, patients with different types of prostate cancer metastasis had different overall survival rates; for example, in a single metastases organ site, our current study showed that cases of prostate cancer with NRLN metastasis had a lower risk of death than those with bone metastases in the younger group. Adnan *et al.* have also reported that the prognosis of patients with NRLN metastasis was better than those with bone metastasis [@B31]. However, Shou *et al.* demonstrated that there was no difference in prognosis between patients with lung and bone metastasis [@B40]. In addition, our current findings show that patients with liver metastases had the worst overall survival, which is consistent with the findings from a previous study showing that prostate cancer with liver metastasis was associated with a shorter overall survival time [@B41]. Indeed, the probable reason for this finding is because prostate cancer with liver metastasis is often associated with neuroendocrine differentiation (NED) [@B42], which leads to an increase in tumor cell dedifferentiation, androgen receptor deficiency, and resistance to hormone therapy [@B43].

However, our research does have some limitations; for example, we were unable to collect data on endocrine therapy and other variables related to transfer loads, such as quantity, size, and exact location from the SEER database. Moreover, information regarding specific metastasis sites was only available in the SEER database after 2010. Because of this, we may not be able to ensure an adequate sample size and follow-up duration. In addition to the age at diagnosis, several other factors may also affect the overall survival. For example, chemotherapy, radiation therapy, and surgery may be more widely available to young patients with mPCa, whereas elderly patients may have complications that lead to disease progression. Thus, future study should further verify our current data.

5. Conclusions {#Section5}
==============

In conclusion, patients with lung metastases or younger patients (≤ 70 years old) with bone + lung metastases had better prognosis. Thus, patients with other organic metastasis could be treated more aggressively to achieve better overall survival.
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Estimation of the cut-off value for the age stratification as determined by the X-tile software.
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Comparison of the overall survival rates of patients with prostate cancer with single (A) and bone-related (B) metastatic sites analyzed by using the Kaplan-Meier curves.
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###### 

Comparison of the overall survival rates of patients with prostate cancer with single metastatic sites stratified with age, as analyzed by using the Kaplan-Meier curves. A = young aged group (\< 70 years of age), B = middle-aged group (70-82 years of age), C = elderly aged group (\> 82 years of age).
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###### 

Comparison of overall survival of prostate cancer patients with bone-related metastatic sites stratified with age analyzed by using the Kaplan-Meier curves. A = young aged group (≤ 70 years of age), B = middle-aged and elderly aged group (\> 70 years of age).
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###### 

Characteristics of patients with prostate cancer with distant metastasis from SEER 18 population-based registries by age groups.

                                  Total         Age ≤ 70 years   70-82 years   Age \> 82 years   P-value
  ------------------------------- ------------- ---------------- ------------- ----------------- -------------
  Insurance, no. (%)                                                                             **\<0.001**
  Insured                         8188 (80.7)   3997 (74.3)      2717 (86.5)   1474 (90.5)       
  Uninsured                       405 (4.0)     341 (6.3)        47 (1.5)      17 (1.0)          
  Any medicaid                    1261 (12.4)   876 (16.3)       288 (9.2)     97 (6.0)          
  Unkown                          293 (2.9)     164 (3.0)        88 (2.8)      41 (2.5)          
  Marital status, no. (%)                                                                        **\<0.001**
  Married                         5619 (55.4)   2855 (53.1)      1889 (60.2)   875 (53.7)        
  Divorced/widowed                1864 (18.4)   774 (14.4)       581 (18.5)    509 (31.2)        
  singled                         1805 (17.8)   1258 (23.4)      406 (12.9)    141 (8.7)         
  Unkown                          859 (8.5)     491 (9.1)        264 (8.4)     104 (6.4)         
  Race, no. (%)                                                                                  **\<0.001**
  White                           7497 (73.9)   3714 (69.1)      2440 (77.7)   1343 (82.4)       
  Black                           1903 (18.8)   1278 (23.8)      458 (14.6)    167 (10.3)        
  Other                           653 (6.4)     332 (6.2)        212 (6.8)     109 (6.7)         
  Unkown                          94 (0.9)      54 (1.0)         30 (1.0)      10 (0.6)          
  PSA in ng/mL, no. (%)                                                                          **\<0.001**
  ≤20                             1762 (17.4)   978 (18.2)       607 (19.3)    177 (10.9)        
  20-50                           1423 (14.0)   732 (13.6)       474 (15.1)    217 (13.3)        
  ≥50                             6087 (60.0)   3300 (61.4)      1774 (56.5)   1013 (62.2)       
  Unkown                          875 (8.6)     368 (6.8)        285 (9.1)     222 (13.6)        
  Gleason score, no. (%)                                                                         **\<0.001**
  ≤7                              1309 (12.9)   804 (14.9)       404 (12.9)    101 (6.2)         
  8                               1819 (17.9)   1046 (19.4)      581 (18.5)    192(11.8)         
  9                               3448 (34.0)   1914 (35.6)      1085 (34.6)   449 (27.6)        
  10                              752 (7.4)     392 (7.3)        241 (7.7)     119 (7.3)         
  Unkown                          2819 (27.8)   1222 (22.7)      829 (26.4)    768 (47.1)        
  Derived AJCC T stage, no. (%)                                                                  **\<0.001**
  ≤T1                             2654 (26.2)   1443 (26.8)      864 (27.5)    347 (21.3)        
  T2                              2991 (29.5)   1568 (29.2)      987 (31.4)    436 (26.8)        
  T3                              1099 (10.8)   684 (12.7)       308 (9.8)     107 (6.6)         
  T4                              1154 (11.4)   667 (12.4)       317 (10.1)    170 (10.4)        
  Tx                              2249 (22.2)   1016 (18.9)      664 (21.1)    569 (34.9)        
  Derived AJCC N stage, no. (%)                                                                  **\<0.001**
  N0                              5579 (55.0)   2742 (51.0)      1875 (59.7)   962 (59.1)        
  N1                              2829 (27.9)   1814 (33.7)      737 (23.5)    278 (17.1)        
  Nx                              1739 (17.1)   822 (15.3)       528 (16.8)    389 (12.9)        
  Surgery, no. (%)                                                                               **\<0.001**
  Yes                             195 (1.9)     169 (3.1)        21 (0.7)      5 (0.3)           
  No/Unknown                      9952 (98.1)   5209 (96.9)      3119 (99.3)   1624 (99.7)       
  Radiation , no. (%)                                                                            **\<0.001**
  Yes                             2476 (24.4)   1538 (28.6)      678 (21.6)    260 (16.0)        
  No/Unknown                      7671 (75.6)   3840 (71.4)      2462 (78.4)   1369 (84.0)       
  Chemotherapy, no. (%)                                                                          **\<0.001**
  Yes                             1094 (10.8)   808 (15.0)       253 (8.1)     33 (2.0)          
  No/Unknown                      9053 (89.2)   4570 (85.0)      2887 (91.9)   1596 (98.0)       
  Metastasis sites, no. (%)                                                                      **\<0.001**
  NRLN only                       650 (6.4)     401 (7.5)        187 (6.0)     62 (3.8)          
  Bone only                       7161 (70.6)   3565 (66.3)      2339 (74.5)   1257 (77.2)       
  Lung only                       140 (1.4)     65 (1.2)         44 (1.4)      31 (1.9)          
  Liver only                      72 (0.7)      40 (0.7)         19 (0.6)      13 (0.8)          
  Brain only                      17 (0.2)      9 (0.2)          6 (0.2)       1 (0.1)           
  Bone+NRLN                       1313 (12.9)   863 (16.0)       307 (9.8)     143 (8.8)         
  Bone+Lung                       546 (5.4)     296 (5.5)        168 (5.4)     82 (5.0)          
  Bone+Liver                      203 (2.0)     112 (2.1)        58 (1.8)      33 (2.0)          
  Bone+Brain                      45 (0.4)      27 (0.5)         12 (0.4)      6 (0.4)           

Abbreviations: NRLN=non-regional lymph nodes

###### 

Univariate and multivariate analysis of overall survival (OS) rates of patients with single metastases.

                         Unvariate analysis                  Multivariate analysis   
  ---------------------- --------------------- ------------- ----------------------- -------------
  Age                                                                                
  ≤ 70 years             1 (Ref)                             1 (Ref)                 
  70-82 years            1.384 (1.282-1.495)   **\<0.001**                           **\<0.001**
  \> 82 years            2.471 (2.268-2.692)   **\<0.001**   1.600 (1.490-1.718)     **\<0.001**
  Insurance                                    **\<0.001**                           **\<0.001**
  Insured                1 (Ref)                             1 (Ref)                 
  Uninsured              1.021 (0.852-1.224)   0.823         1.077 (0.895-1.295)     0.431
  Any medicaid           1.270 (1.148-1.406)   **\<0.001**   1.233 (1.110-1.370)     **\<0.001**
  Unkown                 0.937 (0.772-1.136)   0.508         1.028 (0.842-1.255)     0.786
  Marital status                               **\<0.001**                           **\<0.001**
  Married                1 (Ref)                             1 (Ref)                 
  Divorced/widowed       1.506 (1.384-1.638)   **\<0.001**   1.263 (1.159-376)       **\<0.001**
  singled                1.223 (1.125-1.352)   **\<0.001**   1.163 (1.056-1.281)     **0.002**
  Unkown                 0.949 (0.835-1.079)   0.427         0.935 (0.819-1.068)     0.322
  Race                                         **\<0.001**                           **\<0.001**
  White                  1 (Ref)                             1 (Ref)                 
  Black                  1.072 (0.985-1.167)   0.106         1.082 (0.991-1.182)     0.079
  Other                  0.767 (0.659-0.893)   **0.001**     0.736 (0.631-0.857)     **\<0.001**
  Unkown                 0.344 (0.185-641)     **0.001**     0.386 (0.207-0.719)     **0.003**
  PSA in ng/mL                                 **\<0.001**                           **\<0.001**
  ≤20                    1 (Ref)                             1 (Ref)                 
  20-50                  1.302 (1.147-1.478)   **\<0.001**   1.214 (1.068-1.379)     **0.003**
  ≥50                    1.855 (1.680-2.048)   **\<0.001**   1.478 (1.334-1.638)     **\<0.001**
  Unkown                 1.955 (1.706-2.240)   **\<0.001**   1.406 (1.221-1.618)     **\<0.001**
  Gleason score                                **\<0.001**                           **\<0.001**
  ≤7                     1 (Ref)                             1 (Ref)                 
  8                      1.410 (1.230-1.617)   **\<0.001**   1.337 (1.165-1.534)     **\<0.001**
  9                      1.934 (1.712-2.185)   **\<0.001**   1.841 (1.627-2.083)     **\<0.001**
  10                     2.697 (2.306-3.154)   **\<0.001**   2.471 (2.108-2.896)     **\<0.001**
  Unkown                 3.061 (2.705-3.463)   **\<0.001**   2.323 (2.027-2.661)     **\<0.001**
  Derived AJCC T stage                         **\<0.001**                           **\<0.001**
  ≤T1                    1 (Ref)                             1 (Ref)                 
  T2                     1.076 (0.984-1.177)   0.109         0.991 (0.905-1.086)     0.854
  T3                     0.840 (0.736-0.957)   **0.009**     0.884 (0.773-1.011)     0.071
  T4                     1.522 (1.350-1.716)   **\<0.001**   1.259 (1.111-1.426)     **\<0.001**
  Tx                     1.725 (1.570-1.894)   **\<0.001**   1.133 (1.006-1.276)     **0.039**
  Derived AJCC N stage                         **\<0.001**                           **0.039**
  N0                     1 (Ref)                             1 (Ref)                 
  N1                     0.875 (0.799-0.958)   **0.004**     0.912 (0.827-1.005)     0.064
  Nx                     1.392 (1.281-1.512)   **\<0.001**   1.062 (0.969-1.163)     0.199
  Surgery                                                                            
  Yes                    0.276 (0.188-0.406)   **\<0.001**   0.579 (0.390-0.860)     **0.007**
  No/Unknown             1 (Ref)                             1 (Ref)                 
  Radiation                                                                          
  Yes                    0.912 (0.843-0.986)   **0.021**     \-                      
  No/Unknown             1 (Ref)                                                     
  Chemotherapy                                                                       
  Yes                    0.919 (0.798-1.058)   0.24          \-                      
  No/Unknown             1 (Ref)                                                     
  Metastasis sites                             **\<0.001**                           **\<0.001**
  Bone only              1 (Ref)                             1 (Ref)                 
  NRLN only              0.606 (0.522-0.702)   **\<0.001**   0.641 (0.548-0.749)     **\<0.001**
  Lung only              0.733 (0.552-0.971)   **0.031**     0.716 (0.539-0.951)     **0.021**
  Liver only             2.045 (1.523-2.745)   **\<0.001**   1.937 (1.439-2.605)     **\<0.001**
  Brain only             1.482 (0.820-2.679)   0.193         1.340 (0.739-2.428)     0.335

Abbreviations: HR=Hazard ratio; CI=confidence interval; NRLN=non-regional lymph nodes

###### 

Univariate and multivariate analysis of overall survival (OS) rates of patients with bone-related metastases.

                         Unvariate analysis                  Multivariate analysis   
  ---------------------- --------------------- ------------- ----------------------- -------------
  Age                                                                                
  ≤ 70 years             1 (Ref)                             1 (Ref)                 
  \> 70 years            1.642 (1.454-1.854)   **\<0.001**   1.545 (1.363-1.752)     **\<0.001**
  Insurance                                    0.559                                 
  Insured                1 (Ref)                             \-                      
  Uninsured              0.859 (0.660-1.120)   0.262                                 
  Any medicaid           0.978 (0.830-1.153)   0.79                                  
  Unkown                 1.174 (0.800-1.723)   0.413                                 
  Marital status                               0.083                                 
  Married                1 (Ref)                             \-                      
  Divorced/widowed       1.216 (1.036-426)     **0.016**                             
  singled                1.115 (0.959-1.298)   0.157                                 
  Unkown                 0.995 (0.786-1.259)   0.964                                 
  Race                                         **0.013**                             **0.003**
  White                  1 (Ref)                             1 (Ref)                 
  Black                  0.904 (0.783-1.044)   0.171         0.868 (0.750-1.005)     0.058
  Other                  0.766 (0.590-0.994)   **0.045**     0.708 (0.545-0.920)     **0.01**
  Unkown                 0.091 (0.013-0.644)   **0.016**     0.110 (0.015-0.783)     **0.028**
  PSA in ng/mL                                 **0.008**                             
  ≤20                    1 (Ref)                             \-                      
  20-50                  1.071 (0.821-1.396)   0.614                                 
  ≥50                    1.071 (0.880-1.304)   0.495                                 
  Unkown                 1.577 (1.182-2.104)   **0.002**                             
  Gleason score                                **\<0.001**                           **\<0.001**
  ≤7                     1 (Ref)                             1 (Ref)                 
  8                      0.912 (0.695-1.197)   0.507         0.903 (0.687-1.187)     0.464
  9                      1.189 (0.936-1.510)   0.157         1.187 (0.933-1.512)     0.163
  10                     1.649 (1.238-2.195)   **0.001**     1.670 (1.250-2.231)     **0.001**
  Unkown                 1.597 (1.266-2.015)   **\<0.001**   1.398 (1.094-1.786)     **0.007**
  Derived AJCC T stage                         **\<0.001**                           **0.006**
  ≤T1                    1 (Ref)                             1 (Ref)                 
  T2                     1.142 (0.944-1.381)   0.17          1.060 (0.875-1.285)     0.552
  T3                     1.023 (0.796-1.315)   0.861         0.996 (0.773-1.284)     0.978
  T4                     1.511 (1.235-1.848)   **\<0.001**   1.394 (1.134-1.713)     **0.002**
  Tx                     1.432 (1.188-1.725)   **\<0.001**   1.198 (0.971-1.478)     0.091
  Derived AJCC N stage                         0.17                                  
  N0                     1 (Ref)                             \-                      
  N1                     0.929 (0.811-1.065)   0.291                                 
  Nx                     1.086 (0.906-1.303)   0.372                                 
  Surgery                                                                            
  Yes                    0.726 (0.362-1.457)   0.368                                 
  No/Unknown             1 (Ref)                             \-                      
  Radiation                                                                          
  Yes                    1.181 (1.031-1.353)   **0.016**     1.221 (1.064-1.401)     **0.004**
  No/Unknown             1 (Ref)                             1 (Ref)                 
  Chemotherapy                                                                       
  Yes                    0.731 (0.592-0.903)   **0.004**     0.674 (0.544-0.836)     **\<0.001**
  No/Unknown             1 (Ref)                             1 (Ref)                 
  Metastasis sites                             **\<0.001**                           **\<0.001**
  Bone+NRLN              1 (Ref)                             1 (Ref)                 
  Bone+Lung              1.171 (1.015-1.352)   **0.03**      1.198 (1.036-1.384)     **0.015**
  Bone+Liver             2.137 (1.785-2.559)   **\<0.001**   2.167 (1.805-2.603)     **\<0.001**
  Bone+Brain             1.762 (1.234-2.515)   **0.002**     1.684 (1.174-2.416)     **0.005**

Abbreviations: HR=Hazard ratio; CI=confidence interval; NRLN=non-regional lymph nodes

###### 

Multivariate Cox regression analysis of overall survival (OS) rates of the single metastatic site by age groups

  Age ≤ 70 years     Multivariate analysis                 70-82 years        Multivariate analysis                 Age \> 82 years    Multivariate analysis   
  ------------------ ----------------------- ------------- ------------------ ----------------------- ------------- ------------------ ----------------------- -----------
  Metastasis sites                           **\<0.001**   Metastasis sites                           **\<0.001**   Metastasis sites                           **0.016**
  Bone only          1 (Ref)                               Bone only          1 (Ref)                               Bone only          1 (Ref)                 
  NRLN only          0.590 (0.475-0.734)     **\<0.001**   NRLN only          0.632 (0.487-0.821)     **0.001**     NRLN only          0.754 (0.523-1.088)     0.131
  Lung only          0.737 (0.468-1.161)     0.189         Lung only          0.429 (0.242-0.761)     **0.004**     Lung only          1.412 (0.857-2.327)     0.176
  Liver only         2.088 (1.362-3.202)     **0.001**     Liver only         1.439 (0.811-2.551)     0.213         Liver only         2.327 (1.240-4.369)     **0.009**
  Brain only         2.260 (0.913-5.337)     0.079         Brain only         0.968 (0.358-2.612)     0.948         Brain only         2.024 (0.499-8.210)     0.324

Abbreviations: HR=Hazard ratio; CI=confidence interval; NRLN=non-regional lymph nodes

###### 

Multivariate Cox regression analysis of overall survival (OS) rates of the bone-related metastases sites by age groups.

  Age ≤ 70 years     Multivariate analysis                 Age \> 70 years    Multivariate analysis   
  ------------------ ----------------------- ------------- ------------------ ----------------------- -------------
  Metastasis sites                           \<**0.001**   Metastasis sites                           \<**0.001**
  Bone+NRLN          1 (Ref)                               Bone+NRLN          1 (Ref)                 
  Bone+Lung          0.937 (0.762-1.151)     0.534         Bone+Lung          1.544 (1.254-1.900)     \<**0.001**
  Bone+Liver         2.203 (1.725-2.815)     \<**0.001**   Bone+Liver         2.222(1.688-2.926)      \<**0.001**
  Bone+Brain         1.952 (1.202-3.169      **0.007**     Bone+Brain         1.538 (0.889-2.661)     0.123

Abbreviations: HR=Hazard ratio; CI=confidence interval; NRLN=non-regional lymph nodes
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